What is Janux Therapeutics's market cap?

Janux Therapeutics (JANX) has a market capitalization of $949.5M and trades on NASDAQ.

What is Janux Therapeutics's revenue and profitability?

Janux Therapeutics generated $13.7M in trailing twelve-month revenue with a net loss of $114.5M, representing a net margin of -833.6%, with free cash flow of -$78.5M. These figures are based on the Q1 2026 filing.

Who are Janux Therapeutics's competitors?

Janux Therapeutics's key competitors include CytomX Therapeutics, Johnson & Johnson, Amgen, and others. These companies compete in similar markets and product categories.

Who does Janux Therapeutics partner with?

Janux Therapeutics's notable partners include Merck Sharp & Dohme Corp., Bristol Myers Squibb, WuXi Biologics (Hong Kong) Limited.

Where is Janux Therapeutics headquartered?

Janux Therapeutics is headquartered in United States of America and employs approximately 68 people. It has been publicly traded since 2021.

Janux Therapeutics

JANX

Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and autoimmune diseases.

Market cap

$949.53M-33.8%

Revenue$13.7M+47.1%

Net income-$114.5M-47.3%

Free cash flow-$78.5M-68.7%

EPS (diluted)-$1.84-36.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$3.7MMiss by $625.6K EPS-$0.39Beat by $0.13

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$19.1M

EPS estimate-$0.26

Financials

Q1 2026

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation & ratios

Valuation

See full

Market cap$949.53M-33.8%

Enterprise value$919.27M-38.0%

P/S69.1×-3,375×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

AbbVie$453.91B+36.3%

Amgen$203.07B+25.3%

Regeneron Pharmaceuticals$69.9B+16.0%

Xencor$1.5B+129%

Cullinan Therapeutics, Inc.$1.1B+121%

Janux Therapeutics$949.5M-37.2%

CytomX Therapeutics$707.5M+87.9%

By revenue growth

Janux Therapeutics+47.1%

AbbVie+9.5%

Amgen+9.1%

Johnson & Johnson+8.1%

Regeneron Pharmaceuticals+5.9%

Xencor-23.5%

CytomX Therapeutics-75.9%

By net margin

Regeneron Pharmaceuticals29.65%-2.3pp

Johnson & Johnson21.48%-3.5pp

Amgen20.96%+3.6pp

AbbVie5.79%-1.5pp

CytomX Therapeutics-166.4%-195pp

Xencor-177.1%-13.9pp

Cullinan Therapeutics, Inc.-346.14%—

Janux Therapeutics-833.6%-0.9pp

Profile

Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies for cancer and autoimmune diseases. The company utilizes its proprietary TRACTr, TRACIr, and ARM platforms to engineer tumor-activated T cell engagers and bispecific antibodies designed to maximize anti-tumor activity while minimizing systemic toxicities like cytokine release syndrome. Its core value proposition lies in its masking technology, which keeps therapeutics inactive in healthy tissue and triggers activation only within the tumor microenvironment.

Competitive position

A clinical-stage innovator in the protease-activated biologic space, competing with established pharmaceutical firms by offering potentially safer, off-the-shelf alternatives to CAR T-cell therapies.

GeographiesUnited States, Global

Customer segmentsPharmaceutical companies, Clinical trial participants, Healthcare systems

Business modelR&D intensive, Licensing and Royalties, Strategic Collaborations

SuppliersContract Manufacturing Organizations (CMOs), Raw material suppliers, Clinical research organizations (CROs), Cell line providers

CustomersStrategic pharmaceutical partners, Specialty pharmacies, Hospitals and oncology clinics

CountryUnited States of America

Listed2021

Employees68.0

CEODavid Alan Campbell

SectorHealthcare

IndustryBiotechnology

Websitejanuxrx.com

FilingsSEC EDGAR

Ask your AI about Janux Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's market cap?: Janux Therapeutics (JANX) has a market capitalization of $949.5M and trades on NASDAQ.
What is Janux Therapeutics's revenue and profitability?: Janux Therapeutics generated $13.7M in trailing twelve-month revenue with a net loss of $114.5M, representing a net margin of -833.6%, with free cash flow of -$78.5M. These figures are based on the Q1 2026 filing.
Who are Janux Therapeutics's competitors?: Janux Therapeutics's key competitors include CytomX Therapeutics, Johnson & Johnson, Amgen, and others. These companies compete in similar markets and product categories.
Who does Janux Therapeutics partner with?: Janux Therapeutics's notable partners include Merck Sharp & Dohme Corp., Bristol Myers Squibb, WuXi Biologics (Hong Kong) Limited.
Where is Janux Therapeutics headquartered?: Janux Therapeutics is headquartered in United States of America and employs approximately 68 people. It has been publicly traded since 2021.